There are differences in the strategy, Andrx works with brand-name pharmaceutical companies to develop controlled-release formulations of existing generic drugs. They are not just another generic producer trying to compete against companies like Ivax but to develop controlled release formulations of existing generic drugs. Nobody is working on as many formulations of controlled release medications as Andrx. Few companies have the in-house technolgy that Andrx has. Then you have to look at who runs the show, and alliances. You must do your research. Watson Pharmaceuticals owns a 19% stake in Andrx. Your probably saying who is Watson? Watson has a 50/50 partnership with Andrx to produce 8 new generics, all with three year excusivity. And many other little pacts. Andrx is working more globally as well as strong alliances in China. Follow Watson as well, you will get some insight into Andrx, also check out South Florida Business Journal On-line to get some additional info. Also recent Forbes article in Forbes, "This generic is a buy" (Watson) Look into the company and its
JV's they are impressive, look at the price, almost everyone who owns it, including many insider's payed more than 15. The little guys hoping to turn a quick buck, are selling. I know of many investment firms who were trying to hoard the stock, for their select customer's.
Nobody does all this work, unless they expect big dividends as well. |
